The cAMP-dependent protein kinase pathway as therapeutic target - possibilities and pitfalls

Current Topics in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 1393-1405

  Kleppe, Rune ^a   Krakstad, Camilla ^b   Selheim, Frode ^a   Kopperud, Reidun ^a   Doskeland, Stein Ove ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

cAMP; Cell signaling; Disease; Multi targeting; PKA

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RECEPTOR; CYCLIC GMP;

ARTICLE; BACTERIAL VIRULENCE; BINDING SITE; BLOOD CELL; CARDIOVASCULAR SYSTEM; CATALYSIS; CENTRAL NERVOUS SYSTEM; DRUG TARGETING; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; IMMUNE SYSTEM; MEMORY; MOOD DISORDER; NERVE DEGENERATION; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958155542     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795589629     Document Type: Article

References (146)

1. Kim, C.; Cheng, C. Y.; Saldanha, S. A.; Taylor, S. S. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell, 2007, 130 (6), 1032-1043.
2. Alverdi, V.; Mazon, H.; Versluis, C.; Hemrika, W.; Esposito, G.; van den Heuvel, R.; Scholten, A.; Heck, A. J. cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J. Mol. Biol., 2008, 375 (5), 1380-1393.
3. Ellison, K. E.; Gandhi, G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs, 2005, 65 (6), 787-797.
4. McKeage, K.; Keam, S. J. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2009, 69 (13), 1799-828.
5. Menendez, R.; Kelly, H. W. Theophylline therapy. J. Asthma, 1983, 20 (6), 455-466.
6. Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.; Naylor, A. M.; Osterloh, I. H.; Gingell, C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res., 1996, 8 (2), 47-52.
7. Jaski, B. E.; Fifer, M. A.; Wright, R. F.; Braunwald, E.; Colucci, W. S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J. Clin. Invest., 1985, 75 (2), 643-649.
8. Kamenetsky, M.; Middelhaufe, S.; Bank, E. M.; Levin, L. R.; Buck, J.; Steegborn, C. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J. Mol. Biol., 2006, 362 (4), 623-639.
9. Cooper, D. M. Regulation and organization of adenylyl cyclases and cAMP. Biochem. J., 2003, 375 (Pt 3), 517-529.
10. Watson, P. A.; Giger, K. E.; Kempinski, A. M. Type I and type VIII adenylyl cyclases constitute a family whose activation is coupled to cellular deformation through the action of calciumcalmodulin. Biochem. Cell Biol., 1995, 73 (7-8), 367-372.
11. Mittag, T. W.; Guo, W. B.; Kobayashi, K. Bicarbonate-activated adenylyl cyclase in fluid-transporting tissues. Am. J. Physiol., 1993, 264 (6 Pt 2), F1060-1064.
12. Chen, Y.; Cann, M. J.; Litvin, T. N.; Iourgenko, V.; Sinclair, M. L.; Levin, L. R.; Buck, J. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science, 2000, 289 (5479), 625-628.
13. Zaccolo, M.; Movsesian, M. A. cAMP and cGMP signaling crosstalk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res., 2007, 100 (11), 1569-1578.
14. Movsesian, M.; Stehlik, J.; Vandeput, F.; Bristow, M. R. Phosphodiesterase inhibition in heart failure. Heart Fail. Rev., 2009, 14 (4), 255-263.
15. Kleppisch, T. Phosphodiesterases in the central nervous system. Handb. Exp. Pharmacol., 2009, (191), 71-92.
16. Grant, P. G.; Colman, R. W. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry, 1984, 23 (8), 1801-1807.
17. Heikaus, C. C.; Pandit, J.; Klevit, R. E. Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. Structure, 2009, 17 (12), 1551-1557.
18. Houslay, M. D.; Adams, D. R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J., 2003, 370 (Pt 1), 1-18.
19. Takio, K.; Smith, S. B.; Krebs, E. G.; Walsh, K. A.; Titani, K. Amino acid sequence of the regulatory subunit of bovine type II adenosine cyclic 3',5'-phosphate dependent protein kinase. Biochemistry, 1984, 23 (18), 4200-4206.
20. Titani, K.; Sasagawa, T.; Ericsson, L. H.; Kumar, S.; Smith, S. B.; Krebs, E. G.; Walsh, K. A. Amino acid sequence of the regulatory subunit of bovine type I adenosine cyclic 3',5'-phosphate dependent protein kinase. Biochemistry, 1984, 23 (18), 4193-4199.
21. Ogreid, D.; Ekanger, R.; Suva, R. H.; Miller, J. P.; Sturm, P.; Corbin, J. D.; Doskeland, S. O. Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination. Principles for optimizing the isozyme specificity of analog combinations. Eur. J. Biochem., 1985, 150 (1), 219-227.
22. Francis, S. H.; Corbin, J. D. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci., 1999, 36 (4), 275-328.
23. Brandon, E. P.; Idzerda, R. L.; McKnight, G. S. PKA isoforms, neural pathways, and behaviour: making the connection. Curr. Opin. Neurobiol., 1997, 7 (3), 397-403.
24. Amieux, P. S.; Cummings, D. E.; Motamed, K.; Brandon, E. P.; Wailes, L. A.; Le, K.; Idzerda, R. L.; McKnight, G. S. Compensatory regulation of RIalpha protein levels in protein kinase A mutant mice. J. Biol. Chem., 1997, 272 (7), 3993-3998.
25. Brandon, E. P.; Zhuo, M.; Huang, Y. Y.; Qi, M.; Gerhold, K. A.; Burton, K. A.; Kandel, E. R.; McKnight, G. S.; Idzerda, R. L. Hippocampal long-term depression and depotentiation are defective in mice carrying a targeted disruption of the gene encoding the RI beta subunit of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA, 1995, 92 (19), 8851-8855.
26. Adams, M. R.; Brandon, E. P.; Chartoff, E. H.; Idzerda, R. L.; Dorsa, D. M.; McKnight, G. S. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc. Natl. Acad. Sci. USA, 1997, 94 (22), 12157-12161.
27. Uhler, M. D.; Chrivia, J. C.; McKnight, G. S. Evidence for a second isoform of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem., 1986, 261 (33), 15360-15363.
28. Showers, M. O.; Maurer, R. A. A cloned bovine cDNA encodes an alternate form of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem., 1986, 261 (35), 16288-16291.
29. Beebe, S. J.; Oyen, O.; Sandberg, M.; Froysa, A.; Hansson, V.; Jahnsen, T. Molecular cloning of a tissue-specific protein kinase (C gamma) from human testis--representing a third isoform for the catalytic subunit of cAMP-dependent protein kinase. Mol. Endocrinol., 1990, 4 (3), 465-475.
30. Beebe, S. J.; Salomonsky, P.; Jahnsen, T.; Li, Y. The C gamma subunit is a unique isozyme of the cAMP-dependent protein kinase. J. Biol. Chem., 1992, 267 (35), 25505-25512.
31. Chiorini, J. A.; Zimmermann, B.; Yang, L.; Smith, R. H.; Ahearn, A.; Herberg, F.; Kotin, R. M. Inhibition of PrKX, a novel protein kinase, and the cyclic AMP-dependent protein kinase PKA by the regulatory proteins of adeno-associated virus type 2. Mol. Cell. Biol., 1998, 18 (10), 5921-5929.
32. Desseyn, J. L.; Burton, K. A.; McKnight, G. S. Expression of a nonmyristylated variant of the catalytic subunit of protein kinase A during male germ-cell development. Proc. Natl. Acad. Sci. USA, 2000, 97 (12), 6433-6438.
33. Jedrzejewski, P. T.; Girod, A.; Tholey, A.; Konig, N.; Thullner, S.; Kinzel, V.; Bossemeyer, D. A conserved deamidation site at Asn 2 in the catalytic subunit of mammalian cAMP-dependent protein kinase detected by capillary LC-MS and tandem mass spectrometry. Protein Sci., 1998, 7 (2), 457-469.
34. Kinzel, V.; Konig, N.; Pipkorn, R.; Bossemeyer, D.; Lehmann, W. D. The amino terminus of PKA catalytic subunit--a site for introduction of posttranslational heterogeneities by deamidation: DAsp2 and D-isoAsp2 containing isozymes. Protein Sci., 2000, 9 (11), 2269-2277.
35. Skalhegg, B. S.; Huang, Y.; Su, T.; Idzerda, R. L.; McKnight, G. S.; Burton, K. A. Mutation of the Calpha subunit of PKA leads to growth retardation and sperm dysfunction. Mol. Endocrinol., 2002, 16 (3), 630-639.
36. Funderud, A.; Aas-Hanssen, K.; Aksaas, A. K.; Hafte, T. T.; Corthay, A.; Munthe, L. A.; Orstavik, S.; Skalhegg, B. S. Isoformspecific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA). Cell Signal., 2009, 21 (2), 274-281.
37. Reinton, N.; Orstavik, S.; Haugen, T. B.; Jahnsen, T.; Tasken, K.; Skalhegg, B. S. A novel isoform of human cyclic 3',5'-adenosine monophosphate-dependent protein kinase, c alpha-s, localizes to sperm midpiece. Biol. Reprod., 2000, 63 (2), 607-611.
38. Orstavik, S.; Reinton, N.; Frengen, E.; Langeland, B. T.; Jahnsen, T.; Skalhegg, B. S. Identification of novel splice variants of the human catalytic subunit Cbeta of cAMP-dependent protein kinase. Eur. J. Biochem., 2001, 268 (19), 5066-5073.
39. Funderud, A.; Henanger, H. H.; Hafte, T. T.; Amieux, P. S.; Orstavik, S.; Skalhegg, B. S. Identification, cloning and characterization of a novel 47 kDa murine PKA C subunit homologous to human and bovine Cbeta2. BMC Biochem., 2006, 7, 20.
40. Kvissel, A. K.; Orstavik, S.; Oistad, P.; Rootwelt, T.; Jahnsen, T.; Skalhegg, B. S. Induction of Cbeta splice variants and formation of novel forms of protein kinase A type II holoenzymes during retinoic acid-induced differentiation of human NT2 cells. Cell Signal., 2004, 16 (5), 577-587.
41. Huang, Y.; Roelink, H.; McKnight, G. S. Protein kinase A deficiency causes axially localized neural tube defects in mice. J. Biol. Chem., 2002, 277 (22), 19889-19896.
42. Howe, D. G.; Wiley, J. C.; McKnight, G. S. Molecular and behavioral effects of a null mutation in all PKA C beta isoforms. Mol. Cell. Neurosci., 2002, 20 (3), 515-524.
43. Zimmermann, B.; Chiorini, J. A.; Ma, Y.; Kotin, R. M.; Herberg, F. W. PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I. J. Biol. Chem., 1999, 274 (9), 5370-5378.
44. de Rooij, J.; Rehmann, H.; van Triest, M.; Cool, R. H.; Wittinghofer, A.; Bos, J. L. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J. Biol. Chem., 2000, 275 (27), 20829-20836.
45. de Rooij, J.; Zwartkruis, F. J.; Verheijen, M. H.; Cool, R. H.; Nijman, S. M.; Wittinghofer, A.; Bos, J. L. Epac is a Rap1 guaninenucleotide-exchange factor directly activated by cyclic AMP. Nature, 1998, 396 (6710), 474-477.
46. Niimura, M.; Miki, T.; Shibasaki, T.; Fujimoto, W.; Iwanaga, T.; Seino, S. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. J. Cell. Physiol., 2009, 219 (3), 652-658.
47. Ueno, H.; Shibasaki, T.; Iwanaga, T.; Takahashi, K.; Yokoyama, Y.; Liu, L. M.; Yokoi, N.; Ozaki, N.; Matsukura, S.; Yano, H.; Seino, S. Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform. Genomics, 2001, 78 (1-2), 91-98.
48. Rehmann, H.; Arias-Palomo, E.; Hadders, M. A.; Schwede, F.; Llorca, O.; Bos, J. L. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. Nature, 2008, 455 (7209), 124-127.
49. Rehmann, H.; Das, J.; Knipscheer, P.; Wittinghofer, A.; Bos, J. L. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. Nature, 2006, 439 (7076), 625-628.
50. Ponsioen, B.; Gloerich, M.; Ritsma, L.; Rehmann, H.; Bos, J. L.; Jalink, K. Direct spatial control of Epac1 by cyclic AMP. Mol. Cell. Biol., 2009, 29 (10), 2521-2531.
51. Aumo, L.; Rusten, M.; Mellgren, G.; Bakke, M.; Lewis, A. E. Functional roles of protein kinase A (PKA) and exchange protein directly activated by 3',5'-cyclic adenosine 5'-monophosphate (cAMP) 2 (EPAC2) in cAMP-mediated actions in adrenocortical cells. Endocrinology, 2010, 151 (5), 2151-2161.
52. Biel, M.; Michalakis, S. Cyclic nucleotide-gated channels. Handb. Exp. Pharmacol., 2009, (191), 111-136.
53. Fesenko, E. E.; Kolesnikov, S. S.; Lyubarsky, A. L. Induction by cyclic GMP of cationic conductance in plasma membrane of retinal rod outer segment. Nature, 1985, 313 (6000), 310-313.
54. Distler, M.; Biel, M.; Flockerzi, V.; Hofmann, F. Expression of cyclic nucleotide-gated cation channels in non-sensory tissues and cells. Neuropharmacology, 1994, 33 (11), 1275-1282.
55. Kingston, P. A.; Zufall, F.; Barnstable, C. J. Rat hippocampal neurons express genes for both rod retinal and olfactory cyclic nucleotide-gated channels: novel targets for cAMP/cGMP function. Proc. Natl. Acad. Sci. USA, 1996, 93 (19), 10440-10445.
56. Cadd, G. G.; Uhler, M. D.; McKnight, G. S. Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides. J. Biol. Chem., 1990, 265 (32), 19502-19506.
57. Dostmann, W. R.; Taylor, S. S. Identifying the molecular switches that determine whether (Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-dependent protein kinase I. Biochemistry, 1991, 30 (35), 8710-8716.
58. Kopperud, R.; Christensen, A. E.; Kjarland, E.; Viste, K.; Kleivdal, H.; Doskeland, S. O. Formation of inactive cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions. J. Biol. Chem., 2002, 277 (16), 13443-13448.
59. Viste, K.; Kopperud, R. K.; Christensen, A. E.; Doskeland, S. O. Substrate enhances the sensitivity of type I protein kinase a to cAMP. J. Biol. Chem., 2005, 280 (14), 13279-13284.
60. Dao, K. K.; Teigen, K.; Kopperud, R.; Hodneland, E.; Schwede, F.; Christensen, A. E.; Martinez, A.; Doskeland, S. O. Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. J. Biol. Chem., 2006, 281 (30), 21500-21511.
61. Wu, J.; Brown, S. H.; von Daake, S.; Taylor, S. S. PKA type IIalpha holoenzyme reveals a combinatorial strategy for isoform diversity. Science, 2007, 318 (5848), 274-279.
62. McNicholl, E. T.; Das, R.; Sildas, S.; Taylor, S. S.; Melacini, G. Communication between tandem cAMP-binding domains in the regulatory subunit of protein kinase A (PKA)-I{alpha} as revealed by domain-silencing mutations. J. Biol. Chem., 2010, 285 (20), 15523-15537.
63. Kim, C.; Xuong, N. H.; Taylor, S. S. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science, 2005, 307 (5710), 690-696.
64. Wu, J.; Jones, J. M.; Nguyen-Huu, X.; Ten Eyck, L. F.; Taylor, S. S. Crystal structures of RIalpha subunit of cyclic adenosine 5'-monophosphate (cAMP)-dependent protein kinase complexed with (Rp)-adenosine 3',5'-cyclic monophosphothioate and (Sp)-adenosine 3',5'-cyclic monophosphothioate, the phosphothioate analogues of cAMP. Biochemistry, 2004, 43 (21), 6620-6629.
65. Byeon, I. J.; Dao, K. K.; Jung, J.; Keen, J.; Leiros, I.; Doskeland, S. O.; Martinez, A.; Gronenborn, A. M. Allosteric communication between cAMP binding sites in the RI subunit of protein kinase A revealed by NMR. J. Biol. Chem., 2010, 285 (18), 14062-14070.
66. Kornev, A. P.; Taylor, S. S. Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta, 2010, 1804 (3), 440-444.
67. Kopperud, R.; Krakstad, C.; Selheim, F.; Doskeland, S. O. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett., 2003, 546 (1), 121-126.
68. Maeno, H.; Johnson, E. M.; Greengard, P. Subcellular distribution of adenosine 3',5'-monophosphate-dependent protein kinase in rat brain. J. Biol. Chem., 1971, 246 (1), 134-142.
69. Vallee, R. B.; DiBartolomeis, M. J.; Theurkauf, W. E. A protein kinase bound to the projection portion of MAP 2 (microtubuleassociated protein 2). J. Cell. Biol., 1981, 90 (3), 568-576.
70. Carr, D. W.; Stofko-Hahn, R. E.; Fraser, I. D.; Bishop, S. M.; Acott, T. S.; Brennan, R. G.; Scott, J. D. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J. Biol. Chem., 1991, 266 (22), 14188-14192.
71. Kinderman, F. S.; Kim, C.; von Daake, S.; Ma, Y.; Pham, B. Q.; Spraggon, G.; Xuong, N. H.; Jennings, P. A.; Taylor, S. S. A dynamic mechanism for AKAP binding to RII isoforms of cAMPdependent protein kinase. Mol. Cell., 2006, 24 (3), 397-408.
72. Gold, M. G.; Lygren, B.; Dokurno, P.; Hoshi, N.; McConnachie, G.; Tasken, K.; Carlson, C. R.; Scott, J. D.; Barford, D. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol. Cell., 2006, 24 (3), 383-395.
73. Newlon, M. G.; Roy, M.; Morikis, D.; Hausken, Z. E.; Coghlan, V.; Scott, J. D.; Jennings, P. A. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat. Struct. Biol., 1999, 6 (3), 222-227.
74. Pidoux, G.; Tasken, K. Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. J. Mol. Endocrinol., 2010, 44 (5), 271-284.
75. Lim, C. J.; Han, J.; Yousefi, N.; Ma, Y.; Amieux, P. S.; McKnight, G. S.; Taylor, S. S.; Ginsberg, M. H. Alpha4 integrins are type I cAMP-dependent protein kinase-anchoring proteins. Nat. Cell Biol., 2007, 9 (4), 415-421.
76. Huang, L. J.; Durick, K.; Weiner, J. A.; Chun, J.; Taylor, S. S. Identification of a novel protein kinase A anchoring protein that binds both type I and type II regulatory subunits. J. Biol. Chem., 1997, 272 (12), 8057-8064.
77. Kapiloff, M. S.; Piggott, L. A.; Sadana, R.; Li, J.; Heredia, L. A.; Henson, E.; Efendiev, R.; Dessauer, C. W. An adenylyl cyclasemAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes. J. Biol. Chem., 2009, 284 (35), 23540-23546.
78. Di Benedetto, G.; Zoccarato, A.; Lissandron, V.; Terrin, A.; Li, X.; Houslay, M. D.; Baillie, G. S.; Zaccolo, M. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ. Res., 2008, 103 (8), 836-844.
79. Zaccolo, M.; Di Benedetto, G.; Lissandron, V.; Mancuso, L.; Terrin, A.; Zamparo, I. Restricted diffusion of a freely diffusible second messenger: mechanisms underlying compartmentalized cAMP signalling. Biochem. Soc. Trans., 2006, 34 (Pt 4), 495-497.
80. DeLange, R. J.; Kemp, R. G.; Riley, W. D.; Cooper, R. A.; Krebs, E. G. Activation of skeletal muscle phosphorylase kinase by adenosine triphosphate and adenosine 3',5'-monophosphate. J. Biol. Chem., 1968, 243 (9), 2200-2208.
81. Petersen, R. K.; Madsen, L.; Pedersen, L. M.; Hallenborg, P.; Hagland, H.; Viste, K.; Doskeland, S. O.; Kristiansen, K. Cyclic AMP (cAMP)-mediated stimulation of adipocyte differentiation requires the synergistic action of Epac-and cAMP-dependent protein kinase-dependent processes. Mol. Cell Biol., 2008, 28 (11), 3804-3816.
82. Zhao, A. Z. Control of food intake through regulation of cAMP. Curr. Top. Dev. Biol., 2005, 67, 207-224.
83. Wang, Z.; Li, V.; Chan, G. C.; Phan, T.; Nudelman, A. S.; Xia, Z.; Storm, D. R. Adult type 3 adenylyl cyclase-deficient mice are obese. PLoS One, 2009, 4 (9), e6979.
84. Cummings, D. E.; Brandon, E. P.; Planas, J. V.; Motamed, K.; Idzerda, R. L.; McKnight, G. S. Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A. Nature, 1996, 382 (6592), 622-626.
85. Newhall, K. J.; Cummings, D. E.; Nolan, M. A.; McKnight, G. S. Deletion of the RIIbeta-subunit of protein kinase A decreases body weight and increases energy expenditure in the obese, leptindeficient ob/ob mouse. Mol. Endocrinol., 2005, 19 (4), 982-991.
86. Metrich, M.; Lucas, A.; Gastineau, M.; Samuel, J. L.; Heymes, C.; Morel, E.; Lezoualc'h, F. Epac mediates beta-adrenergic receptorinduced cardiomyocyte hypertrophy. Circ. Res., 2008, 102 (8), 959-965.
87. Bogatcheva, N. V.; Zemskova, M. A.; Kovalenkov, Y.; Poirier, C.; Verin, A. D. Molecular mechanisms mediating protective effect of cAMP on lipopolysaccharide (LPS)-induced human lung microvascular endothelial cells (HLMVEC) hyperpermeability. J. Cell Physiol., 2009, 221 (3), 750-759.
88. Aslam, M.; Hartel, F. V.; Arshad, M.; Gunduz, D.; Abdallah, Y.; Sauer, H.; Piper, H. M.; Noll, T. cAMP/PKA antagonizes thrombin-induced inactivation of endothelial myosin light chain phosphatase: role of CPI-17. Cardiovasc. Res., 2010, 87 (2), 375-384.
89. Birukova, A. A.; Birukov, K. G.; Adyshev, D.; Usatyuk, P.; Natarajan, V.; Garcia, J. G.; Verin, A. D. Involvement of microtubules and Rho pathway in TGF-beta1-induced lung vascular barrier dysfunction. J. Cell Physiol., 2005, 204 (3), 934-947.
90. Sehrawat, S.; Cullere, X.; Patel, S.; Italiano, J. Jr.; Mayadas, T. N. Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function. Mol. Biol. Cell, 2008, 19 (3), 1261-1270.
91. Surapisitchat, J.; Jeon, K. I.; Yan, C.; Beavo, J. A. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ. Res., 2007, 101 (8), 811-818.
92. Birukova, A. A.; Zagranichnaya, T.; Alekseeva, E.; Bokoch, G. M.; Birukov, K. G. Epac/Rap and PKA are novel mechanisms of ANPinduced Rac-mediated pulmonary endothelial barrier protection. J. Cell Physiol., 2008, 215 (3), 715-724.
93. Hatzelmann, A.; Morcillo, E. J.; Lungarella, G.; Adnot, S.; Sanjar, S.; Beume, R.; Schudt, C.; Tenor, H. The preclinical pharmacology of roflumilast-A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol. Ther., 2010, 23 (4), 235-256.
94. Schwarz, U. R.; Walter, U.; Eigenthaler, M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol., 2001, 62 (9), 1153-1161.
95. Fabre, J. E.; Gurney, M. E. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol. Biosyst., 2010, 6 (2), 305-315.
96. Colman, R. W. Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis. Semin. Thromb. Hemost., 2004, 30 (4), 451-460.
97. Haslam, R. J.; Dickinson, N. T.; Jang, E. K. Cyclic nucleotides and phosphodiesterases in platelets. Thromb. Haemost., 1999, 82 (2), 412-423.
98. Jensen, B. O.; Selheim, F.; Doskeland, S. O.; Gear, A. R.; Holmsen, H. Protein kinase A mediates inhibition of the thrombininduced platelet shape change by nitric oxide. Blood, 2004, 104 (9), 2775-2782.
99. Schafe, G. E.; LeDoux, J. E. Memory consolidation of auditory pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J. Neurosci., 2000, 20 (18), RC96.
100. Kaplan, M. P.; Abel, T. Genetic approaches to the study of synaptic plasticity and memory storage. CNS Spectr., 2003, 8 (8), 597-610.
101. Malleret, G.; Alarcon, J. M.; Martel, G.; Takizawa, S.; Vronskaya, S.; Yin, D.; Chen, I. Z.; Kandel, E. R.; Shumyatsky, G. P. Bidirectional regulation of hippocampal long-term synaptic plasticity and its influence on opposing forms of memory. J. Neurosci., 2010, 30 (10), 3813-25.
102. Lee, H. K.; Barbarosie, M.; Kameyama, K.; Bear, M. F.; Huganir, R. L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature, 2000, 405 (6789), 955-959.
103. Sealfon, S. C.; Olanow, C. W. Dopamine receptors: from structure to behavior. Trends Neurosci., 2000, 23 (10 Suppl), S34-40.
104. Millan, M. J.; Marin, P.; Bockaert, J.; la Cour, C. M. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci., 2008, 29 (9), 454-464.
105. Almas, B.; Le Bourdelles, B.; Flatmark, T.; Mallet, J.; Haavik, J. Regulation of recombinant human tyrosine hydroxylase isozymes by catecholamine binding and phosphorylation. Structure/activity studies and mechanistic implications. Eur. J. Biochem., 1992, 209 (1), 249-255.
106. Winge, I.; McKinney, J. A.; Ying, M.; D'Santos, C. S.; Kleppe, R.; Knappskog, P. M.; Haavik, J. Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem. J., 2008, 410 (1), 195-204.
107. Zhang, H. T. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr. Pharm. Des., 2009, 15 (14), 1688-1698.
108. Bourgault, S.; Vaudry, D.; Dejda, A.; Doan, N. D.; Vaudry, H.; Fournier, A. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Curr. Med. Chem., 2009, 16 (33), 4462-4480.
109. Shelton, R. C.; Hal Manier, D.; Lewis, D. A. Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls. Int. J. Neuropsychopharmacol., 2009, 12 (9), 1223-1232.
110. Dwivedi, Y.; Rizavi, H. S.; Shukla, P. K.; Lyons, J.; Faludi, G.; Palkovits, M.; Sarosi, A.; Conley, R. R.; Roberts, R. C.; Tamminga, C. A.; Pandey, G. N. Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol. Psychiatry, 2004, 55 (3), 234-243.
111. Liang, Z.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C. X. Downregulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J. Neurochem., 2007, 103 (6), 2462-2470.
112. Peters-Golden, M. Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Sci. Signal., 2009, 2 (75), pe37.
113. Wall, E. A.; Zavzavadjian, J. R.; Chang, M. S.; Randhawa, B.; Zhu, X.; Hsueh, R. C.; Liu, J.; Driver, A.; Bao, X. R.; Sternweis, P. C.; Simon, M. I.; Fraser, I. D. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKAAKAP95-p105. Sci. Signal, 2009, 2 (75), ra28.
114. Bryn, T.; Mahic, M.; Enserink, J. M.; Schwede, F.; Aandahl, E. M.; Tasken, K. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J. Immunol., 2006, 176 (12), 7361-7370.
115. Agarwal, N.; Lamichhane, G.; Gupta, R.; Nolan, S.; Bishai, W. R. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature, 2009, 460 (7251), 98-102.
116. Torgersen, K. M.; Aandahl, E. M.; Tasken, K. Molecular architecture of signal complexes regulating immune cell function. Handb. Exp. Pharmacol., 2008, (186), 327-363.
117. Mattapallil, J. J.; Douek, D. C.; Hill, B.; Nishimura, Y.; Martin, M.; Roederer, M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature, 2005, 434 (7037), 1093-1097.
118. Barnitz, R. A.; Wan, F.; Tripuraneni, V.; Bolton, D. L.; Lenardo, M. J. Protein Kinase A phosphorylation activates Vpr-induced cell cycle arrest during Human Immunodeficiency Virus Type-1 infection. J. Virol., 2010, 84 (13), 6410-6424.
119. Nokta, M. A.; Pollard, R. B. Human immunodeficiency virus replication: modulation by cellular levels of cAMP. AIDS Res. Hum. Retroviru., 1992, 8 (7), 1255-1261.
120. Mongillo, M.; Tocchetti, C. G.; Terrin, A.; Lissandron, V.; Cheung, Y. F.; Dostmann, W. R.; Pozzan, T.; Kass, D. A.; Paolocci, N.; Houslay, M. D.; Zaccolo, M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ. Res., 2006, 98 (2), 226-234.
121. Lin, D. T.; Fretier, P.; Jiang, C.; Vincent, S. R. Nitric oxide signaling via cGMP-stimulated phosphodiesterase in striatal neurons. Synapse, 2010, 64 (6), 460-466.
122. Jager, R.; Schwede, F.; Genieser, H. G.; Koesling, D.; Russwurm, M. Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. Br J Pharmacol., 2010, 161 (7), 1645-1660.
123. Pierre, S.; Eschenhagen, T.; Geisslinger, G.; Scholich, K. Capturing adenylyl cyclases as potential drug targets. Nat. Rev. Drug Discov., 2009, 8 (4), 321-335.
124. Kikura, M.; Morita, K.; Sato, S. Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. Pharmacol. Res., 2004, 49 (3), 275-281.
125. Buck, J.; Levin, L. R.; Mühlschlegel, F. A. Chemical inhibitors of soluble Adeneylyl cyclase (SAC). Patent Number 2005, WO/2005/070419.
126. Christensen, A. E.; Selheim, F.; de Rooij, J.; Dremier, S.; Schwede, F.; Dao, K. K.; Martinez, A.; Maenhaut, C.; Bos, J. L.; Genieser, H. G.; Doskeland, S. O. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J. Biol. Chem., 2003, 278 (37), 35394-35402.
127. Ogreid, D.; Ekanger, R.; Suva, R. H.; Miller, J. P.; Doskeland, S. O. Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs. Eur. J. Biochem., 1989, 181 (1), 19-31.
128. Rehmann, H.; Schwede, F.; Doskeland, S. O.; Wittinghofer, A.; Bos, J. L. Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac. J. Biol. Chem., 2003, 278 (40), 38548-38556.
129. Birkeland, E.; Nygaard, G.; Oveland, E.; Mjaavatten, O.; Ljones, M.; Doskeland, S. O.; Krakstad, C.; Selheim, F. Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. J. Proteomics Bioinform., 2009, 2 (6), 244-254.
130. Laxman, S.; Riechers, A.; Sadilek, M.; Schwede, F.; Beavo, J. A. Hydrolysis products of cAMP analogs cause transformation of Trypanosoma brucei from slender to stumpy-like forms. Proc. Natl. Acad. Sci. USA, 2006, 103 (50), 19194-19199.
131. Poppe, H.; Rybalkin, S. D.; Rehmann, H.; Hinds, T. R.; Tang, X. B.; Christensen, A. E.; Schwede, F.; Genieser, H. G.; Bos, J. L.; Doskeland, S. O.; Beavo, J. A.; Butt, E. Cyclic nucleotide analogs as probes of signaling pathways. Nat. Methods, 2008, 5 (4), 277-278.
132. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2 (7), 358-364.
133. Wong, S.; Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol., 2004, 22, 247-306.
134. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351 (Pt 1), 95-105.
135. Bogoyevitch, M. A.; Fairlie, D. P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today, 2007, 12 (15-16), 622-633.
136. Shomin, C. D.; Meyer, S. C.; Ghosh, I. Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling. Bioorg. Med. Chem., 2009, 17 (17), 6196-6202.
137. Carlson, C. R.; Lygren, B.; Berge, T.; Hoshi, N.; Wong, W.; Tasken, K.; Scott, J. D. Delineation of type I protein kinase Aselective signaling events using an RI anchoring disruptor. J. Biol. Chem., 2006, 281 (30), 21535-21545.
138. Torheim, E. A.; Jarnaess, E.; Lygren, B.; Tasken, K. Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. Biochem. J., 2009, 424 (1), 69-78.
139. Morrison, D. K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol., 2009, 19 (1), 16-23.
140. Meiri, D.; Greeve, M. A.; Brunet, A.; Finan, D.; Wells, C. D.; LaRose, J.; Rottapel, R. Modulation of Rho guanine exchange factor Lfc activity by protein kinase A-mediated phosphorylation. Mol. Cell. Biol., 2009, 29 (21), 5963-5973.
141. Diviani, D.; Abuin, L.; Cotecchia, S.; Pansier, L. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J., 2004, 23 (14), 2811-2820.
142. Wurtele, M.; Jelich-Ottmann, C.; Wittinghofer, A.; Oecking, C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J., 2003, 22 (5), 987-994.
143. Whitehouse, S.; Feramisco, J. R.; Casnellie, J. E.; Krebs, E. G.; Walsh, D. A. Studies on the kinetic mechanism of the catalytic subunit of the cAMP-dependent protein kinase. J. Biol. Chem., 1983, 258 (6), 3693-3701.
144. Petukhov, S. P.; Grivennikov, I. A.; Bulargina, T. V.; Severin, E. S. [Kinetic mechanism of phosphotransferase reactions catalyzed by cAMP-dependent protein kinase type I and type II from rabbit skeletal muscle]. Biokhimiia, 1984, 49 (8), 1367-1374.
145. Zhou, J.; Adams, J. A. Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase. Biochemistry, 1997, 36 (50), 15733-15738.
146. Shaffer, J.; Adams, J. A. Detection of conformational changes along the kinetic pathway of protein kinase A using a catalytic trapping technique. Biochemistry, 1999, 38 (37), 12072-12079.